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Abstract
Summary Sixty patients diagnosed with generalized anxiety
disorder and treated with either paroxetine, sertraline, or
citalopram for at least 12 months were enrolled in this study,
and the bone mineral density (BMD) of the patients was
compared with that of 40 healthy volunteers. Selective sero-
tonin reuptake inhibitor (SSRI) therapy in generalized anxiety
disorder was found to be related with decreased BMD values.
Introduction The objectives of this study were to evaluate the
effect of SSRI therapy on BMD in postmenopausal women
diagnosed with generalized anxiety disorder (GAD) and to
identify the effects of the duration of disease and treatment on
risk factors for osteoporosis.
Methods Sixty patients diagnosed with GAD and treated with
paroxetine, sertraline, or citalopram from the SSRI group for
at least 12months were enrolled. Social demographic features,
the Hamilton Anxiety Scale (HAS) results, and the Hamilton
Depression Scale (HDS) scores of all the patients were
assessed. The BMD of the patients was measured by dual-
energy X-ray absorptiometry (DXA) at the femoral and lum-
bar regions. The patients were divided into three groups which
are the paroxetine, sertraline, and citalopram groups. The
BMD of the patients was compared with that of 40 healthy
volunteers.
Results The L2–L4, total lumbar vertebrae, femoral
intertrochanteric, total femoral Z-scores, and femoral Ward’s
region T-scores of the treatment group were lower than the
median T- and Z-scores of the control group (p<0.05). Of the
treatment groups, the femoral neck, trochanteric and
intertrochanteric T- and Z-scores, total femoral T- and Z-
scores, and femoral Ward’s T- and Z-scores of the sertraline
group were significantly lower than the BMD values mea-
sured at the identical regions in the paroxetine and citalopram
groups (p<0.05).There was a significant negative correlation
between the duration of treatment and the BMD values.
Conclusion SSRI therapy in GAD was found to be related
with decreased BMD values. Further randomized controlled
studies are warranted to determine whether SSRI use is a risk
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factor for osteoporosis; such studies should investigate these
factors by performing BMD assessments before treatment.
Keywords BMD . GAD . Osteoporosis . SSRI
Introduction
Generalized anxiety disorder (GAD) is a chronic anxiety
disorder with a lifetime incidence rate of 4–6 % that could
be accompanied by other physical diseases. Selective seroto-
nin reuptake inhibitors are the most commonly prescribed
antidepressants for GAD. Generalized anxiety disorder and
selective serotonin reuptake inhibitor therapy could be accom-
panied by various biological alterations throughout the sys-
tems of the body. In recent years, one of the most investigated
biological alterations is osteoporosis. According to the World
Health Organization (WHO), osteoporosis (OP) is a silent
epidemic characterized by a predisposition to enhanced bone
fragility and an increased risk of fracture [1]. Patterson-
Buckendahl et al. showed that anxiety disorders influence
bone metabolism by demonstrating that psychological stress
causes a decrease in osteocalcin levels which increase during
the construction of bone and concluded that chronic stress has
a negative influence on growth [2]. In another study,
concerning bone mineral density and anxiety-depression
symptoms, it was shown that increased anxiety levels are
correlated with decreased bone mineral density [3].
Although the studies investigating the effects of SSRIs on
BMD are limited, these studies showed the negative effects of
these drugs on BMD [4, 5]. In a study with bone cell culture, it
was shown that the serotonergic pathway has a role in
converting a mechanical stimulus into a chemical stimulus
and that SSRI usage has negative effects on bone density,
particularly in developing bones [6]. Richards et al. showed
that SSRIs are clinically related to bone fragility, fall risk, a
doubled risk of fracture, and decreasing BMD scores [7].
Functional serotonin receptors are present in osteoblasts and
osteocytes. In in vitro media, these receptors stimulate the
reproduction of osteoblasts in mice and facilitate differentia-
tion in human osteoclasts. Serotonin receptors (5HT2B) aid
osteogenic differentiation in cell cultures [8]. A decrease in
bone mass and strength and changes in bone structure are
shown in mice with serotonin transporter gene defects. Mice
exposed to fluoxetine hydrochloride are shown to have im-
paired bone mineral content and bone formation [9]. These
studies support the hypothesis that the serotonin transporters
in bone cells have an important role in defining bone mass,
structure, and strength.
The objectives of our study are to evaluate the effect of
selective serotonin reuptake inhibitor (SSRI) therapy on bone
mineral density (BMD) in postmenopausal women who are
diagnosed with generalized anxiety disorder, to identify the
effects on the risk factors for osteoporosis of the duration of




A total of 67 consecutive postmenopausal women between the
ages of 50 and 65 years, who were admitted to the Ankara
Numune Training and Research Hospital Psychiatry Depart-
ment outpatient clinic, were enrolled in this study. All the
patients were diagnosed with generalized anxiety disorder
according to the Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV-TR criteria by using Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) and were
treated with sertraline, paroxetine, or citalopram for at least
12 months. The SSRI dosage was in the therapeutic range
although no dose limitation was set; the study is a naturalistic
study. A score of more than seven points on the Hamilton
Depression Scale; mental retardation; being diagnosed with
another first-axis disorder; substance abuse including abuse of
alcohol, the use of other drugs such as antipsychotics, thyroid
hormone, steroids, and mood stabilizers; a disorder causing
osteoporosis; a bone disease; or an endocrinological disease
were the exclusion criteria for the study. A total of seven
patients were excluded from the study including two patients
with comorbid depression, two with hormone replacement
therapy, one using steroids, one with rheumatoid arthritis,
and one using antiepileptic drug.
The control group consisted of 40 healthy volunteers with
no history of psychiatric disease who matched the criteria of
the patients were enrolled in the study. The approval of the
Ethics Committee was obtained. The patients were informed,
and written informed consent forms were obtained from all of
the participants.
Measurements
A sociodemographic data form was completed for all of the
participants. Additionally, examination was administered to
the patients, including a physical examination, height and
weight measurements, and a body mass index (BMI) assess-
ment, and a smoking history (never smokers or current/former
smokers) was taken from each patient. The BMD measure-
ments were performed in the Ankara Numune Training and
Research Hospital Radiology Department. Bone mineral den-
sity assessment was performed by DXA in all of the patients at
the right-hip femoral neck, trochanteric, intertrochanteric, and
Ward’s regions.
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Structured clinical interview for DSM-IVaxis I disorders
An interview form developed by Spitzer et al. was used,
Turkish reliability and validity, for the DSM-IVAxis I diag-
nosis that was used in the study [10].
Hamilton depression scale
A form developed by Hamilton (1960) consisting of 17 ques-
tions was used, and a score of ≥14 indicates depression. The
reliability and validity study of the Turkish version were
conducted by Akdemir et al. [11] (It was used to exclude
patients with major depressive disorder).
Hamilton anxiety scale
The form designed by Hamilton (1959) for determining the
level of anxiety and distribution of symptoms in individuals
was used in the study. The HAS consists of 14 questions that
investigate physical and mental symptoms. The reliability and
validity study of the Turkish version were conducted byYazıcı
et al. [12].
Bone mineral density
The BMD (g/cm2) is performed by DXA in all of the patients
at the right-hip femoral neck and in the trochanteric,
intertrochanteric, and Ward’s regions. The WHO criteria were
used for osteoporosis and osteopenia. According to these
criteria, a T-score<−1 or >−2.5 was defined as osteopenia,
and a T-score≤−2.5 was defined as osteoporosis. The T-score
is the number of standard deviations (SD) from the young
adult mean, and the Z-score is the number of standard devia-
tions above or below the average bone mineral density value
for women of comparable age [13].
Statistical analysis
The statistical analyses were performed using SPSS for Win-
dows Version 11.5. The normality of the constant variables
was determined by the Shapiro-Wilk test. The descriptive
statistics for the constant variables were defined as the mean
±standard deviation, the median (the width between the quar-
ters) or the median (as the minimum and maximum), whereas
the categorical variables were defined by the case number as
the percentage (%). The significance of the difference between
the control and treatment groups for the mean BMI values and
ages was evaluated by Student’s t test. The significance of the
difference between the control group and the individual drug
groups for the mean BMI values and ages was evaluated by a
one-way ANOVA test.
The significance of the differences between the case and
control T- and Z-scores and the T- and Z-scores of the smoking
and non-smoking cases were determined by the Mann-
Whitney U test. The significance of the T- and Z-scores’
changes in the cases and controls was determined by the
Kruskal-Wallis test. If significance were detected, multiple
non-parametric comparison tests were performed to identify
the groups in which significance was defined. The signifi-
cance of the differences in smoking and bone loss between the
groups was calculated by Pearson’s chi-square test. The cor-
relation between the BMD and other variables was determined
by Spearman’s correlation test. Statistical significance was
defined as p<0.05.
Results
The patients in the SSRI group (paroxetine, citalopram and
sertraline) were postmenopausal and were between 50 and
65 years of age. There was no statistically significant differ-
ence between the control and the SSRI groups in terms of age
and smoking history (p>0.05) (Table 1).
The clinical and demographic characteristics of the control
and drug groups are listed in Table 2. There was no statistical
significance between the control and drug groups according to
the BMI and smoking history (Table 2). There was no statisti-
cally significant difference between the drug groups in terms of
the duration of disease and the duration of drug use (Table 1).
The Z-scores of L2, L3, and L4 vertebrae; the total lumbar
vertebral region; the intertrochanteric region; and the total
femoral region and the T-scores of the femoral Ward’s region
were lower in the patient group than those of the identical
regions in the control group. The difference was statistically
significant (p<0.05) (Table 2).
The median Hamilton anxiety scores of the patients were
21 (5.00) in the paroxetine group, 16.5 (9.25) in the citalopram
group, and 18.5 (7.50) in the sertraline group. There was no
statistically significant difference between the groups
(p>0.05).
The Z-scores of L2, L3, and L4 vertebrae and the total
lumbar vertebral region; the T-scores of the femoral neck and
the femoral trochanteric region; and the T- and Z-scores of the
femoral Ward’s regions in the paroxetine group were lower
than those of the identical regions in the control group
(p<0.05) (Table 3).
The Z-scores of L3 and L4 vertebrae and the total lumbar
vertebral regions and the T-scores of the femoral neck, tro-
chanteric region, and femoral Ward’s region were lower in the
citalopram group than those of the identical regions in the
control group (p<0.05) (Table 3).
The Z-scores of L2, L3, and L4 vertebrae; the total lumbar
vertebral region; and the femoral Ward’s region and the T- and
Z-scores of femora l neck , t rochanter ic reg ion ,
intertrochanteric region, and the total femoral region were
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lower in the sertraline group than those of the identical regions
in the control group, which were all statistically significant
(Table 3).
A comparison of the treatment groups and the T- and Z-
scores of the femoral neck, trochanteric region, total femur,
and femoral Ward’s region of the sertraline group were shown
to be lower than those areas of the citalopram and the parox-
etine groups (p<0.05) (Table 3).
There was a medium correlation between the BMI and the
Z-score of the L1 vertebra (r=0.096, p<0.05), a low correla-
tion between the BMI and the Z-score of the L2 vertebra (r=
0.226, p<0.05), a low correlation between the BMI and the Z-
score of the L4 vertebra (r=0.210, p<0.05), a medium corre-
lation between the BMI and the Z-score of the femoral neck
(r=0.347, p<0.05), a medium correlation between the BMI
and the T- and Z-scores of the trochanteric region (r=0.244,
p<0.05; r=0,307, p<0,05), a medium correlation between the
BMI and the T- and Z-scores of intertrochanteric region (r=
0.334, p<0.05; r=0.387, p<0.05), a medium correlation be-
tween the BMI and the T- and Z-scores of the total femoral
region (r=0.277, p<0.05; r=0.336, p<0.05), and a low cor-
relation between the BMI and the Z-score of the femoral
Ward’s region (r=0.241, p<0.05). All of the correlations were
statistically significant.
In the patient group, smokers had lower femoral trochan-
teric T-scores, femoral intertrochanteric T- and Z-scores, total
femoral T- and Z-scores, and femoral Ward’s region Z-scores,
which were statistically significant.
Of all the patients, there was no statistically significant
correlation between the duration of disease and the T- and Z-
scores measured at L1–L4, the total lumbar, femoral neck,
femoral trochanteric, femoral intertrochanteric, total femoral,
and femoral Ward’s regions (p>0.05).
Of all the patients, there was a medium negative correlation
between the duration of treatment and the L1 vertebral T- and
Z-scores (r=−0.537, p<0.05; r=−0.547, p<0.05), a medium
negative correlation with the L2 vertebral T- and Z-scores (r=
−0.508, p<0.05; r=−0.608, p<0.05), a weak negative corre-
lation with the L3 vertebral T- and Z-scores (r=0.424,
p<0.05; r=−0.459, p<0.05), a weak negative correlation with
the L4 vertebral T- and Z-scores (r=−0.396, p<0.05; r=
−0.310, p<0.05), a weak negative correlation with the total
lumbar vertebral T- and Z-scores (r=−0.420, p<0.05; r=
−0.405, p<0.05), a weak negative correlation between the
femoral neck trochanteric region T- and Z-scores (r=−0.406,
p<0.05; r=−419, p<0,05), a weak negative correlation with
the intertrochanteric Z-scores (r=−0.28, p<0.05), a weak
negative correlation with the total femoral T- and Z-scores
(r=−0.328, p<0.05; r=−0.339, p<0.05), and a weak negative
correlation with the femoral Ward’s region T- and Z-scores
(r=−0.401, p<0.05; r=−0.333, p<0.05).
Table 1 Demographic characteristics of control and SSRI groups
Variables Control (n=40) Paroxetine (n=20) Citalopram (n=20) Sertraline (n=20) p
Age (year) 56.5±4.2 55.0±0.6 56.9±3.2 56.2±2.6 0.261a
Body Mass Index 28.8±3.7 27.2±4.6 28.7±3.2 26.3±3.5 0.069a
Smoking history (current/former users) 12 (30.0 %) 8 (40.0 %) 7 (35.0 %) 8 (40.0 %) 0.830b
Duration of disease (month) – 42 (24–96) 36 (18–120) 48 (24–108) 0.230c
Duration of drug use (month) – 24 (12–36) 24 (12–60) 30 (12–36) 0.182c
Mean drug dose (mg/day) – 30 (20–40) 20 (10–20) 62.5(50–100)
a One-way ANOVA test
b Pearson’s chi-square test
c Kruskal-Wallis test
Table 2 T- and Z-scores for the control and SSRI Groups
Variables Control group SSRI group pa
L1 T −0.95 (1.95) −0.60 (1.38) 0.622
L1 Z 0.05 (1.48) −0.20 (1.10) 0.059
L2 T −1.40 (2.33) −1.00 (1.98) 0.773
L2 Z −0.15 (1.63) −0.55 (1.38) 0.003
L3 T −0.95 (2.15) −1.10 (0.80) 0.303
L3 Z 0.05 (1.68) −0.50 (0.60) <0.001
L4 T −1.45 (1.45) −1.20 (1.10) 0.927
L4 Z −0.40 (1.45) −0.80 (0.80) <0.001
Total L T −1.40 (1.70) −0.80 (1.30) 0.344
Total L Z −0.20 (1.30) −0.70 (1.20) <0.001
Neck T −0.50 (1.28) −0.10 (1.25) 0.126
Neck Z 0.45 (1.38) 0.35 (1.68) 0.057
Troch T −0.30 (1.65) 0.00 (1.28) 0.359
Troch Z 0.15 (1.48) 0.05 (1.30) 0.118
Inter T 0.00 (1.30) −0.20 (1.10) 0.053
Inter Z 0.30 (1.13) −0.10 (1.10) <0.001
Total F T −0.30 (1.45) −0.40 (0.98) 0.772
Total F Z 0.20 (1.20) −0.10 (1.20) 0.002
Ward’s F T −0.75 (1.68) −0.40 (1.58) 0.009
Ward’s F Z 0.75 (1.23) 0.65 (1.68) 0.677
aMann-Whitney U test
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There was no statistically significant correlation between
the Hamilton anxiety scores and the T- and Z-scores of L1–L4,
the total lumbar, the femoral neck, the femoral trochanteric,
femoral intertrochanteric, total femoral, and femoral Ward’s
regions of the patients (p>0.05).
Discussion
The most frequent psychiatric comorbidities observed in pa-
tients with generalized anxiety disorder are major depression
and dysthymia. The comorbidity is 62.4 % with depression
and 40 % with dysthymia [14].
Whereas some studies that investigated the relationship be-
tween depression and osteoporosis reported a decrease in BMD,
others reported that there was no significant difference in BMD
between the patient and control groups [15–21]. Depression has
effects on bone density by changing the hypothalamic-pituitary-
adrenal axis and increasing proinflammatory cytokines such as
interleukin-6 and TNF-α [22]. The non-inclusion of patients
with a score lower than seven on the HDS is important to
exclude the confounding effects of depression on BMD.
The median Hamilton anxiety scores were 21.0 in the
paroxetine group, 16.5 in the citalopram group, and 18.5 in
the sertraline group, which were not significantly correlated
with the BMD scores. No study was found in the literature
regarding this topic in older patients. Dorn et al. investigated
the BMD scores in adolescent girls with anxiety and
depressive symptoms and found that lower BMD scores were
associated with higher anxiety levels [3]. This result might be
a consequence of not excluding depression in this study.
Nicotine addiction is found in 25.8 % of the occurrence of
anxiety disorders in the literature. It has been reported that
nicotine helps in coping with stress by increasing the ACTH
and cortisol levels and that tobacco consumption increases the
risk of osteoporosis, hip fracture, and early menopause [23, 24].
In our study, the T-scores of the femoral trochanteric region, the
T- and Z-scores of the intertrochanteric region, the total femoral
T- and Z-scores, and the femoralWard’s Z-scores were lower in
smoking individuals than in non-smoking individuals.
Osteoporosis is more prevalent in obese individuals [25]. In
our study, the medium BMI scores were over 25 kg/m2 in the
SSRI and control groups. Because there was no significant
statistical difference in the BMI between the groups, it is
important to equalize the effects of the BMI on BMD. Studies
have shown a positive correlation between BMD scores and
the BMI [26]. Our study is consistent with previous studies
showing a positive correlation between the BMI and BMD
scores. The results support the hypothesis that a higher BMI is
a protective factor for osteoporosis.
The results of studies investigating the effects of SSRI use
on BMD vary. Richards et al. evaluated the association be-
tween SSRI use and BMD and fractures; they reported that
SSRI use was associated with decreased BMD, an increased
risk of falling, and a 2-fold increased risk of a clinical fragility
fracture [7]. In a prospective cohort study by Diem et al. of
Table 3 T- and Z-scores for the




b The difference between the con-
trol group and the paroxetine
group was statistically significant
c The difference between the con-
trol group and the sertraline group
was statistically significant
d The difference between the con-
trol group and the citalopram
group was statistically significant
e The difference between the ser-
traline group and the paroxetine
group was statistically significant
f The difference between the ser-
traline group and the citalopram
group was statistically significant
Variables Control Paroxetine Citalopram Sertraline pa
L1 T −0.95 (1.95) −0.60 (0.80) −0.65 (2.28) −0.75 (2.03) 0.326
L1 Z 0.05 (1.48) −0.40 (0.60) −0.10 (1.10) −0.40 (2.10) 0.075
L2 T −1.40 (2.33) −0.50 (1.90) −1.50 (2.98) −1.00 (1.28) 0.992
L2 Z −0.15 (1.63)b,c −0.40 (1.40)b −0.30 (1.80) −0.95 (0.88)c 0.021
L3 T −0.95 (2.15) −1.00 (0.80) −1.00 (1.40) −1.20 (0.75) 0.622
L3 Z 0.05 (1.68)b,c,d −0.50 (0.60)b −0.50 (1.50)d −0.60 (0.90)c 0.002
L4 T −1.45 (1.45) −1.20 (0.60) −1.20 (1.05) −1.20 (1.35) 0.847
L4 Z −0.40 (1.45)b,c,d −0.80 (0.50)b −0.80 (0.65)d −0.85 (1.48)c 0.004
Total L T −1.40 (1.70) −0.80 (1.20) −0.80 (1.28) −1.30 (1.15) 0.756
Total L Z −0.20 (1.30)b,c,d −0.70 (0.68)b −0.70 (1.18)d −0.70 (1.48)c 0.004
Neck T −0.50 (1.28)b,c,d 0.30 (0.50)b,e 0.30 (0.80)d,f −0.95 (0.38)c,e,f <0.001
Neck Z 0.45 (1.38)c 0.40 (0.50)e 0.40 (0.90)f −0.80 (0.55)c,e,f <0.001
Troch T −0.30 (1.65)b,c,d 0.10 (0.50)b,e 0.05 (0.90)d,f −0.95 (1.40)c,e,f <0.001
Troch Z 0.15 (1.48)c 0.50 (0.30)e 0.50 (1.18)f −0.70 (0.93)c,e,f <0.001
Inter T 0.00 (1.30)c −0.20 (0.40)e −0.20 (1.48)f −0.95 (0.55)c,e,f <0.001
Inter Z 0.30 (1.13)c 0.30 (0.40)e 0.30 (1.10)f −0.90 (0.55)c,e,f <0.001
Total F T −0.30 (1.45)c −0.30 (0.60)e −0.30 (1.33)f −0.90 (0.50)c,e,f <0.001
Total F Z 0.20 (1.20)c 0.20 (0.20)e 0.20 (1.53)f −1.00 (0.20)c,e,f <0.001
Ward’s F T −0.75 (1.68)b,d 0.50 (1.00)b,e 0.50 (1.30)d,f −1.10 (0.88)e,f <0.001
Ward’s F Z 0.75 (1.23)b,c 1.30 (0.60)b,e 1.10 (0.90)f −0.50 (0.30)c,e,f <0.001
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2,722 elderly women, including SSRI users, TCA users, and
non-user healthy controls, the hip BMD was measured at the
beginning of treatment and at the end of 4 years, and an
increased rate of bone loss at the hip was shown in the SSRI
users compared to the TCA users and the non-user control
group [5]. The finding in our study that the BMD scores of L2,
L3, and L4 vertebrae, the total lumbar vertebra, the total
femoral neck, femoral trochanteric, and femoral Ward’s re-
gions in patients using SSRIs were significantly lower than
those of the identical regions in the control group was consis-
tent with results in the studies mentioned [4, 5, 7, 27, 28].
Additionally, studies have shown no significant difference
in the BMD scores during SSRI treatment. In these studies, the
effects of SSRIs and TCAs on BMD were usually assessed
together [29]. In a study by Spangler et al., involving 50–79-
year-old postmenopausal women, the bone mineral density of
the hip, spine, and whole body was measured at baseline and
three years, and no statistically significant associations were
observed between depressive symptoms or antidepressant
(SSRI or TCA) therapy and 3-year changes in BMD or frac-
ture risk [30]. In another study by Cummings et al., the effects
of antidepressant use on BMD were evaluated in women over
65 years of age. The BMD values of antidepressant users were
reported to be similar to those of non-antidepressant users
[31]. The results obtained in these studies and the result of
our study might differ because the effects of SSRIs and TCAs
on the BMD have not been evaluated separately. In a study by
Halbreich et al., involving patients on psychotropic therapy
(antidepressants or antipsychotics) for schizophrenia and af-
fective disorders, the lumbar vertebral (L2–L4) BMD values
of the patients were compared with the age- and gender-
expected values, and their BMD values were found to be
lower than the expected values, a finding that was particularly
more pronounced in males [32]. Because untreated patients
were not included in this study, it is not clear whether the
results are diagnosis related, and/or treatment related [33].
The different results obtained from the studies examining
the effects of antidepressant use on BMD might have many
causes. The first of these reasons might be the different
methods used in the studies. In some studies, the BMD scores
were compared with those of healthy subjects, whereas in
other studies, the BMD results were evaluated at the begin-
ning of the study and then during the study. Another factor
could be the different number of subjects enrolled in the
studies. The other element that is difficult to control might
be that the BMD could be affected by hormone levels, nutri-
tion, physical activity, smoking, and alcohol. The most impor-
tant fact might be that the medication used by the subjects for
other medical reasons should be detected for the BMD scores
which is a long process [34–36].
In our study, the T- and Z-scores of the sertraline group at
the femoral neck region, the femoral trochanteric region and
the intertrochanteric region, the total femoral scores, and the
scores in the femoral Ward’s region were lower than those of
the citalopram and paroxetine groups. This difference could be
explained by the longer duration of disease and the longer
treatment period in the sertraline group. No studies have per-
formed subgroup analyses of the drugs used in the treatment.
We did not find a statistically significant correlation be-
tween the duration of disease and the T- and Z-scores of L1–
L4, femoral neck, intertrochanteric region, trochanteric re-
gion, total femur, and femoral Ward’s region. We did not find
any study in the literature that investigated the effects of the
duration of disease and the duration of treatment on the BMD
scores. Not finding a correlation between the duration of
disease, disease severity and BMD scores and discovering a
negative correlation between the duration of treatment and
BMD scores are hypothesized to be related to low BMD
scores resulting from SSRI treatment.
Our study is the first study to perform a subgroup analysis of
SSRI effects on BMD scores. The strengths of our study are as
follows: there are no statistically significant differences be-
tween the groups in terms of factors that might affect BMD
scores such as the BMI and smoking. To equalize the effects on
the BMD scores, the hormone levels were not detected because
all of the subjects in the study were postmenopausal women.
The limitations of our study are as follows: being unable to
document the BMD changes related to postmenopausal osteo-
porosis because sufficient data regarding the menopause dura-
tion of the women were not obtained, not enlisting the antide-
pressant treatment, and not knowing the BMD scores before the
study. BMDmight be decreased with various lifestyle variables.
Our study design did not include nutrition factors, physical
activity, family history of bone loss, calcium and vitamin D
deficiency, and hormonal parameters. Therefore, it is difficult to
test SSRI treatment as a single variable. Additional prospective
and randomized, placebo controlled studies that include these
factors should be performed. This study contained a small
number of subjects, and a particular group of subjects were
enrolled in the study; therefore, these results could not be
generalized to the general population, which is another reason
for more comprehensive studies to be performed.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
References
1. World Health Organization (1994) Assessment of fracture risk and its
application to screening for postmenopausal osteoporosis: report of a
WHO study group (meeting held in Rome from 22 to 25 June 1992)
278 Osteoporos Int (2015) 26:273–279
2. Patterson-Buckendahl P, Rusnak M, Fukuhara K, Kvetnansky R
(2001) Repeated immobilization stress reduces rat vertebral bone
growth and osteocalcin. Am J Physiol Regul Integr Comp Physiol
280(1):79–86
3. Dorn LD, Susman EJ, Pabst S, Huang B, Kalkwarf H, Grimes S
(2008) Association of depressive symptoms and anxiety with bone
mass and density in ever-smoking and never-smoking adolescent
girls. Arch Pediatr Adolesc Med 162(12):1181–1188
4. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-
Connor E, Orwoll E, Bliziotes MM (2007) Association of low bone
mineral density with selective serotonin reuptake inhibitor use by
older men. Arch Intern Med 167(12):1246–1251
5. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes
MM, Ensrud KE (2007) Use of antidepressants and rates of hip bone
loss in older women: the study of osteoporotic fractures. Arch Intern
Med 167(12):1240–1245
6. Westbroek I, Van der Plas A, De Rooij KE, Klein-Nulend J, Nijweide
PJ (2001) Expression of serotonin receptors in bone. J Biol Chem
276(31):2891–2898
7. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson
HE, Prior JC, Goltzman D (2007) Effect of selective serotonin
reuptake inhibitors on the risk of fracture. Arch Intern Med
167(2):188–194
8. Locker M, Bitard J, Collet C, Poliard A, Mutel V, Launay JM,
Kellerman O (2006) Stepwise control of osteogenic differentiation
by 5-HT (2B) receptor signaling: nitric oxide production and phos-
pholipase A2 activation. Cell Signal 18(5):628–639
9. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH
(2005) Inhibition of the serotonin (5-hydroxytryptamine) trans-
porter reduces bone accrual during growth. Endocrinology
146(2):685–693
10. Öztürkçigil A, Aydemir Ö, Yıldız M, Danaca AE, Köroğlu E (1999)
DSM-IV Eksen Bozuklukları için Yapılandırılmış Klinik
Görüşmenin Türkçeye Uyarlanması ve Güvenirlik Çalışması. İlaç
Tedavisi Dergisi 12:233–266
11. Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H (1996)
Hamilton depresyon derecelendirme ölçeği (HDDÖ)’nin geçerliği,
güvenirl iğ i ve klinikte kullan ım ı . Psikiyatri Psikoloji
Psikofarmakoloji Dergisi 4(4):251–259
12. Yazıcı MK, Demir B, Tanrıverdi N (1998) Hamilton Anksiyete
Degerlendirme Ölceği; Degerlendiriciler Arası Güvenirlik ve
Geçerlik Çalısması. Turk Psikiyatri Derg 9:114–117
13. Kutsal Gökçe Y (1998) Osteoporozda Görüntüleme Yöntemleri ve
Histomorfometre. İstanbul, pp 81–103
14. Witchen HU, Zhao S, Kessler RC, Eaton WW (1994) DSM-III-R
generalized anxiety disorder in the National Comorbidity Survey.
Arch Gen Psychiatry 51(5):355–364
15. Özsoy S, Eşel E, Turan T, KulaM, Demir H, Kartalcı Ş, Kökbudak Z
(2005) Depresyonlu hastalarda kemik mineral yoğunluğunda
değişiklik var mı? Turk Psikiyatri Derg 16(2):77–82
16. Michelson D, Stratakis C, Hill L, Reynolods J, Galliven E, Chrousos
G, Gold P (1996) Bone mineral density in women with depression. N
Engl J Med 335(16):1176–1181
17. Yazıcı KM, Akıncı A, Sütçü A, Özçakar L (2003) Bone mineral
density in premenopausal women with major depressive disorder.
Psychiatry Res 117(3):271–275
18. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA,
Nicholson GC, Pasco JA (2008) Selective serotonin reuptake inhib-
itor use and bone mineral density in women with a history of
depression. Int Clin Psychopharmacol 23(2):84–87
19. Wu Q, Magnus JH, Liu J, Bencaz AF, Hentz JG (2009) Depression
and low bone mineral density: a meta-analysis of epidemiologic
studies. Osteoporos Int 20(8):1309–1320
20. Moura C, Bernatsky S, Abrahamowicz M, Papaioannou A, Bessette
L, Adachi J, Goltzman D, Prior J, Kreiger N, Towheed T, Leslie WD,
Keiser S, Ioannidis G, Pickard L, Fraser LA, Rahme E (2014)
Antidepressant use and 10-year incident fracture risk: the
population-based Canadian Multicentre Osteoporosis Study
(CaMoS). Osteoporos Int 25(5):1473–1481
21. Erez HB, Weller A, Vaisman N, Kreitler S (2012) The relationship of
depression, anxiety and stress with low bone mineral density in post-
menopausal women. Arch Osteoporos 7(1–2):247–255
22. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK,
Lanctôt KL (2010) Ameta-analysis of cytokines in major depression.
Biol Psychiatry 67(5):446–457
23. Pomerleau OF, Pomerleau CS (1991) Research on stress and
smoking: progress and problems. Br J Addict 86(5):599–603
24. Ortego-Centeno N, Munoz-Torres M, Jodar E, Hernandez-Quero J,
Jurado-Duce A, de la Higuera T-PJ (1997) Effect of tobacco con-
sumption on bone mineral density in healthy young males. Calcif
Tissue Int 60(6):496–500
25. Lindsay R, Cosman F (2001) Osteoporozis. In: Braundwald E, Fauci
AS, Isselbacher KJ (eds) Harrison’s principles of internal medicine.
McGraw- Hill, New York, p 342
26. Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM,
O’Keane V (2004) Effects of long-term prolactin-raising antipsy-
chotic medication on bone mineral density in patients with schizo-
phrenia. Br J Psychiatry 184:503–508
27. Chen F, Hahn TJ, Weintraub NT (2012) Do SSRIs play a role in
decreasing bone mineral density? JAMDA 13(5):413–417
28. Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY (2013)
Relationship between use of antidepressants and risk of fractures: a
meta-analysis. Osteoporos Int 24(1):121–137
29. Ginzburg R, Rosero E (2009) Risk of fractures with selective
serotonin-reuptake inhibitors or tricyclic antidepressants. Ann
Pharmacother 43(1):98–103
30. Spangler L, Scholes D, Brunner RL, Robbins J, Reed SD, Newton
KM, Melville JL, Lacroix AZ (2008) Depressive symptoms, bone
loss, and fractures in postmenopausal women. J Gen Intern Med
23(5):567–574
31. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA,
Orwoll ES (2006) BMD and risk of hip and nonvertebral fractures
in older men: a prospective study and comparison with older women.
J Bone Miner Res 21(10):1550–1556
32. Halbreich U, Palter S (1996) Accelerated osteoporosis in psychiatric
patients: possible pathophysiological processes. Schizophr Bull
22(3):447–454
33. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J,
Bakhai Y, Rosan R et al (1995) Decreased bone mineral density in
medicated psychiatric patients. Psychosom Med 57(5):485–491
34. AbrahamG, PaingWW, Kaminski J, Joseph A, Kohegyi E, Josiassen
RC (2003) Effects of elevated serum prolactin on bone mineral
density and bone metabolism in female patients with schizophrenia:
a prospective study. Am J Psychiatry 160(9):1618–1620
35. Keely EJ, Reiss JP, Drinkwater DT, Faiman C (1997) Bone mineral
density, sex hormones, and long-term use of neuroleptic agents in
men. Endocr Pract 3(4):209–213
36. Chau K, Atkinson SA, Taylor VH (2012) Are selective serotonin
reuptake inhibitors a secondary cause of low bone density? J
Osteoporos 2012
Osteoporos Int (2015) 26:273–279 279
